{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052093","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.251767+00:00","generated_at":"2026-06-03T00:48:39.131148+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ALX Oncology loses two directors; board drops below majority independent; cure period triggered","bullets":["Jack Nielsen resigned April 28 for health; Itziar Canamasas resigned April 30 due to new professional role.","Board reduced to six directors, only three independent, breaching Nasdaq majority requirement.","Company invokes 180-day cure period under Nasdaq Rule 5605(b)(1)(A) to restore independent majority.","Scott Garland reclassified from Class III to Class II director, effective May 1.","Audit, Compensation, and Governance committees reconstituted with Garland, Goodman, Hemrajani."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052093","json":"https://secwatch.observer/filing/0000950170-24-052093.json","markdown":"https://secwatch.observer/filing/0000950170-24-052093.md","text":"https://secwatch.observer/filing/0000950170-24-052093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024052093/0000950170-24-052093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024052093/alxo-20240428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:48:39.131148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a011330667","claim":"Itziar Canamasas resigned as member of the Board of Directors at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"On April 30, 2024, Itziar Canamasas, Ph.D., informed the Company of her resignation as a member of the Board and all committees thereof, effective immediately, due to her taking a new professional position that does not permit her to continue on as a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024052093/0000950170-24-052093-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"ad834f637d","claim":"Jack Nielsen resigned as member of the Board of Directors at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"On April 28, 2024, Jack Nielsen informed ALX Oncology Holdings Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and all committees thereof, effective immediately, due to health reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024052093/0000950170-24-052093-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}